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Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central
obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia. NAFLD is becoming the most common liver disease in con-
temporary society, with the highest prevalence in those over 60 years. NAFLD pathology ranges from simple steatosis to a necroin-
ﬂammatory ﬁbrosing disorder called steatohepatitis (SH), the latter associated with high risk of developing cirrhosis, often oc-
curing in the seventh to ninth decades of life. While the main health implications of NAFLD are increased risk of developing T2D,
cardiovascular diseases, and common cancers, there is substantantially increased standardized mortality, and deaths from decom-
pensated cirrhosis and hepatocellular carcinoma (HCC). Little is known about the interactive eﬀects of ageing and NAFLD, with
most studies focusing on the younger population. This paper summarises the epidemiology, pathogenesis, and clinical course of
NAFLD, with particular attention to persons over age 60 years. An approach to the management of NASH and its complications in
the elderly, will also be presented here.
1.Introduction
In 1980, Ludwig and colleagues introduced the concept of
nonalcoholic steatohepatitis (NASH) to describe liver histo-
logic changes resembling alcoholic hepatitis in individuals
without signiﬁcant alcohol intake [1]. NASH is now concep-
tualized as part of a pathological spectrum of a fatty liver
disorders caused by metabolic factors and referred to col-
lectively as nonalcoholic fatty liver disease (NAFLD). The
mildest form of NAFLD is simple steatosis, characterised by
hepatic fat (triglyceride, TG) accumulation alone. In NASH,
hepatic necroinﬂammatory changes are also present and
a characteristic perisinusoidal pattern of liver ﬁbrosis is
common. Up to 25% of NAFLD patients have NASH, and
in perhaps one third of such cases there is slowly progressive
liver ﬁbrosis leading to cirrhosis. Primary liver cancer (hep-
atocellular carcinoma, HCC) is now a recognized complica-
tion of NAFLD, usually but not always after development of
cirrhosis [2–5]
Ludwig’s descriptions of NASH suggested higher preva-
lenceinwomen,particularlyinthosewhoareobeseandhave
type 2 diabetes (T2D) [1]. Over the last decade, community-
based studies have found male predominance of NAFLD
from the paediatric population [6]u pt oﬁ f t hd e c a d eo fl i f e
in adults. After age 60 years, however, females overtake their
male counterparts in prevalence of NAFLD [7], an age and
gender distribution that resembles that of cardiovascular
disease. This is not surprising given similar risk factors for
NAFLD and cardiovascular diseases.
Most cases of NAFLD occur in overweight or obese indi-
viduals, and there are particular strong links to central obe-
sity, T2D, atherogenic dyslipidemia, and hypertension, each
of which are elements of metabolic syndrome [8, 9]. NAFLD
can now be regarded as the hepatic manifestation of the
metabolic syndrome, although it is not yet included as a
deﬁnitional component. The links between NAFLD and
metabolic syndrome/prediabetes/T2D seem likely to reﬂect
the operation of shared pathogenic factors, as we and others
have reviewed [10–12]. Thus, the presence of fatty liver is
a strong, independent predictor for the future development
of metabolic syndrome [13–15], T2D, and cardiovascular
events. A minority of cases of fatty liver (not due to alcohol)2 Current Gerontology and Geriatrics Research
are secondary to speciﬁc etiologic agents such as drugs or
occur in well-deﬁned settings (jejuno-ileal bypass, total par-
enteral nutrition); they are not regarded as NAFLD (which
infers a metabolic etiology) and will be not discussed further
here [12, 16, 17].
In this paper, we will ﬁrst review the epidemiology and
pathophysiology of NAFLD, with particular focus on age-
related aspects. We will then examine risk factors for devel-
oping progressive liver injury and how known age-related
changes in liver biology might contribute to severity of the
disease among older people. The paper will conclude with
some comments about management strategies that may be
applicable to older individuals with fatty liver.
2. Epidemiology
2.1. Diagnosis. The current diagnosis of NAFLD is based
on detection of hepatic steatosis by liver biopsy or imaging,
exclusionofotherliverdiseases,particularlyalcoholandhep-
atitis C, and recognition of metabolic risk factors. The true
prevalence of NASH, the most clinically relevant subset of
patients with NAFLD, has been diﬃcult to establish because
this is a histologic diagnosis. The diagnosis of NAFLD often
comes to light because of detection of abnormal liver tests,
particularly raised serum alanine aminotransferase (ALT)
and gamma-glutamyl transpeptidase (GGT) and serum fer-
ritin.
All noninvasive methods for diagnosis of NAFLD have
limitations—computerised tomography (CT) scan and hep-
atic ultrasonography (US) are relatively insensitive; they can
only detect moderate to severe steatosis [5, 18]. Serum ALT
increase is not only insensitive, but also nonspeciﬁc; values
mayremainwithinthenormalrangeinupto80%ofpatients
with biopsy-proven NAFLD and up to 30% of NASH [19].
Similarly, serum ferritin is a nonspeciﬁc inﬂammatory
marker, but while it is not speciﬁc for diagnosis of NAFLD,
once the diagnosis has been established, serum ferritin has
been shown to be signiﬁcantly more elevated in patients with
NASH compared with those with simple steatosis (SS) [20].
The “gold standard” of NASH diagnosis is liver biopsy.
However, apart from being an unpleasant and occasionally
dangerous test, it is subject to sampling error and ob-
server diﬀerences in histopathologic interpretation. Further,
reported studies of NASH prevalence may suﬀer from selec-
tion and ascertainment biases as liver biopsies were often
performed in speciﬁc groups like the morbidly obese and
diabetics or among highly selected subjects enrolled in
clinical trials [21].
In the last decade, transient elastography (TE) has been
developed as a safe noninvasive alternative to liver biopsy
for assessing liver ﬁbrosis. This technique has been validated
across diﬀerent liver diseases, including NAFLD [22]. A
recent study of 246 biopsy-proven NAFLD patients from
Hong Kong and France suggested decreasing ability to
successfully obtain liver stiﬀness measurements (LSM) with
increasing BMI; measurement was 97% successful with BMI
< 30kg/m2, dropping to only 75% in obese patients, though
this did not reach statistical signiﬁcance [23]. However, the
recent introduction of the “obese” probe allows LSM to be
successfully increased from 45% to 76% in the morbidly
obese (mean BMI > 40kg/m2)[ 24]. In the elderly popula-
tion, TE is a promising noninvasive method of quantifying
liver ﬁbrosis in NAFLD.
2.2. Community Prevalence of NAFLD and NASH: Rising
Global Prevalence. Depending on the screening tool and
whenthe study was performed, estimated community preva-
lence of NAFLD has ranged from 2.8% to 46% [25–27]. In
theDallasHeartStudy,Browningetal.usedprotonmagnetic
resonance spectroscopy (MRS) to quantify hepatic triglyc-
eride (TG) content of 3 major ethnic groups. Hepatic steato-
sis (deﬁned as greater than 5.5% TG content) was noted in
31% overall, with signiﬁcant ethnic variation—45% in his-
panics, 33% in whites, and 24% in blacks [28]. In Japan,
Korea, Taiwan, and China, the use of ultrasonography in
community studies has found rates between 5 and 40% [29],
with an increasing prevalence over the last 20 years [29, 30].
A recent study in predominantly middle-aged American
employees or outpatients (without known liver disease)
found that the prevalence of steatosis by ultrasonography
was 47%; in this study, NASH was conﬁrmed histologically
in 12% of the total cohort or 30% of the ultrasound-
positive subgroup [27]. Another recent analysis of nearly
40,000 patients from three cycles of the National Health
and Nutritional Examination Survey (NHANES) conducted
between 1988 and 2008 showed rising prevalence of NAFLD
from approximately 5% in the 1988–1994 cohort to 11% in
the 2005–2008 cohort; similarly, they also found increasing
contributing of NAFLD as cause for chronic liver disease
rising from 47% to 76% for the earlier and later series,
respectively [31]. These data are consistent with the clinical
observation that NAFLD is now the commonest liver disor-
der seen in liver clinics of Western industrialised countries
[4].
2.3.AgeandthePrevalenceandSeverityofNAFLD. Theprev-
alence of NAFLD in the general population increases with
age; from 1 to 3% in children [32], 5% in teenagers [32, 33],
18% between 20 and 40 years, 39% in those aged 40 to
50 years, and to over 40% in those greater than 70 years
[4, 26, 30, 34, 35]. In general, fatty liver is more prevalent
in men than women up to the age of 60 years. Beyond
menopause, the prevalence of fatty liver rises sharply in
women and exceeds that observed in their male counterparts
[5, 13, 36].
There are currently 2 epidemiological studies that have
reported on fatty liver in individuals over 70 years. The ﬁrst
recruited 91 inpatients from 3 rehabilitation hospitals in
Israel [34], and the second recruited 351 outpatients from a
tertiary liver clinic in UK [37]. In the earlier study, Kagansky
et al. adopted US and CT scan as diagnostic modality for
NAFLD, while Frith et al. used liver biopsies. Both studies
found NAFLD prevalence to exceed 40% in individuals over
70 years old. However, Frith et al. found a high prevalence
of ﬁbrosis (40%) and cirrhosis (14%) in the liver biopsies
of these older individuals, which contradicted ﬁndings
from Kagansky et al. who found no stigmata of chronic
liver disease on clinical examination of their octogenarianCurrent Gerontology and Geriatrics Research 3
cohort. The weakness of the Kagansky study was reliance on
clinical examination for detection of advanced liver disease,
which has very low sensitivity especially in the absence of
decompensated cirrhosis [38].
2.4. Eﬀects of Overweight, Insulin Resistance, and Impaired
Glycemic Control on NAFLD Prevalence. T h ep r e v a l e n c ea n d
severity of NAFLD is also inﬂuenced by presence of met-
abolic risk factors, such as overweight/obesity and T2D. The
prevalence of NAFLD and NASH in T2D are 76% and 22%,
respectively [27]. Furthermore, the prevalence of NAFLD
correlates with the degree of impaired glucose metabolism,
increasing from 27% in subjects with normal fasting glucose
(fastingbloodglucose,FBG<6.1mmol/L),to43%and62%,
respectively, in those with impaired glucose tolerance (FBG
≥ 6.1mmol, but < 7mmol/L) and T2D (FBG > 7.0mmol/L)
[30].Likewise,theprevalenceofNAFLDincreasesinpropor-
tion to body weight category. In the Dionysos study, NAFLD
was present in 24.5%, 67%, and 94% of the normal weight,
overweight, and obese population, respectively [25, 39].
Pooled analysis of liver biopsy reports in bariatric surgery
patients(BMIgreaterthan40kg/m2 orgreaterthan35kg/m2
for those with medical comorbidities) has shown steatosis
and NASH prevalence to be 61% and 36%, respectively,
whereas ﬁbrosis and cirrhosis are present in 16% and 2%,
respectively [4, 25, 26].
However, although NAFLD and NASH are more com-
moninobesepatients,itisnowrecognisedthatsomeofthese
patients do not meet the weight criteria for obesity. Not
surprisingly, this is more common among Asian patients
(even with ethnic-speciﬁc criteria), though it has also been
increasingly recognised in Western Countries [4]. In China,
for example, 40% of patients with NASH do not meet
ethnicity-adjusted BMI for overweight or obesity [40, 41].
However, most patients with NAFLD/NASH whose BMI
is within an ethnically adjusted “normal range” can be
describedas“metabolicallyobese,”wheretheyhaveincreased
visceral fat tissue (VAT) and usually have detectable insulin
resistance (IR) in spite of normal BMI [4, 36, 42].
3. Ageing Changes in Liverand Other Tissues
RelevanttoNAFLD/NASH
Age-related cellular and organ system changes are not uni-
form. In this section, we focus on changes within the liver
and the pattern of fat distribution, the latter with respect to
metabolic characteristics that are relevant to NAFLD.
3.1. The Ageing Liver. Between the ages of 20 and 70, there is
adeclineinhepaticbloodﬂow(by33%),hepaticvolume(up
to 25%), and liver function [43]. The impact of reduction
of liver volume and hepatic blood ﬂow in the elderly is
unclear, but it tends to alter the pharmacokinetic proﬁles of
drugs that undergo mandatory hepatic oxidation [44]. The
octogenarian liver also has fewer, but larger, hepatocytes,
increased polyploidy, and higher binuclear index [44], as
well as a reduction in mitochondria numbers. The later may
impact on oxidative respiration. Additionally, there is a
reduction in bile acid synthesis, with consequent change to
bile acid secretion and bile ﬂow. There is an age-related
decline in hepatic metabolism of LDL cholesterol, leading to
elevated serum cholesterol. The combined eﬀects of changes
in bile acid secretion and cholesterol metabolism likely
contribute to increased serum cholesterol levels and an
increased frequency of gallstones formation.
T h ea g e i n gl i v e rd o e sa p p e a rt ob em o r es u s c e p t i b l et o
the eﬀects of drugs and other toxins, having diminished
regenerative capacity to recover from insults, as evident by
an increase in morbidity and mortality in hepatic resections
in experimental studies in patients greater than 60 years old
[44, 45].
3.2. Age-Related Changes in Body Composition, and Conse-
quences for Metabolic Syndrome. There is an age-linked in-
crease in abdominal adiposity and fat deposition in muscles
(skeletal and cardiac), liver, and bone marrow [46]. The loss
of lean body (muscle) mass is masked by the increase in
total and regional adiposity with ageing. Not surprisingly,
anthropometric indices such as body mass index (BMI) and
waist circumference do not accurately reﬂect total and
regional adiposity as well as they do in younger patients
[46]. Also, the body fat distribution in the elderly is shifted
from subcutaneous adipose tissue (SAT) to VAT locations,
resulting in deleterious metabolic consequences such as IR
[47, 48].
Several studies have now shown increasing prevalence of
the metabolic syndrome with advancing age [49, 50]. Utilis-
ing data collected from 31,126 adult (>20 years) in NHANES
groupfrom1999to2004,Churillaetal.showedanincreasing
likelihood of developing metabolic syndrome with age. Spe-
ciﬁcally, the odds ratio of developing metabolic syndrome
rises from 1.66 to 5.93 in those aged 30–39 years to 60–69
years, respectively. Beyond this, the odds ratio declined
slightly, to 4.39, in those over 80 years old [49].
As discussed before, there is a very strong correlation
between metabolic syndrome and the subsequent develop-
ment of NAFLD conversely, presence of hepatic steatosis is
predictive for development of metabolic syndrome [13, 25,
36,51].Yamadaetal.retrospectivelylookedatapproximately
13,000 individuals undergoing routine health checkup and
found that the incidence of T2D was 2.9% in men with
fatty liver, compared with 0.6% in men without fatty liver.
Similarly, T2D was found in 2.5% of women with fatty
liver compared to 0.4% who did not develop fatty liver on
ultrasound over the 5-years studied period [42]. In light of
these and similar studies, it is not surprising that the age
and gender speciﬁc prevalence trends for NAFLD mirror
those for metabolic syndrome, peaking in middle age, and
decreasing in octogenarians [13, 36, 37, 52].
4. Pathogenesis of NAFLD
The pathogenesis of NAFLD and progression to steatohep-
atitis have not been fully deciphered. In this section, we will
brieﬂy discuss what is known so far, with special reference to
aspects relevant to interactions with ageing.
An older concept of NASH pathogenesis, the so-called
“two-hit” hypothesis of Day and James [58], proposed that4 Current Gerontology and Geriatrics Research
























Figure 1: Mechanism of hepatic steatosis, adapted from Larter et al. 2010 [12], showing also interactions between adipose tissue in diﬀering
sites with liver in the development of insulin resistance (IR). FFA: free fatty acids; SAT: subcutaneous adipose tissue; VAT: visceral adipose
tissue; TG: triglyceride.
hepatocyte TG accumulation resulting from metabolic im-
balance (obesity, IR and diabetes) is what leads to steatosis
(the “ﬁrst hit”) and that the lipid-laden liver is then vul-
nerable to injurious processes (“second hit” insults) such as
cytokines and oxidative stress [58, 59]. Damaged and dying
hepatocytes and/or recruited and activated inﬂammatory
cells, such as Kupﬀer cells, generate other signals (cytokines,
growth factors, and oxidative stress) which activate scar-
forming hepatic stellate cells with resultant development of
liver ﬁbrosis and cirrhosis [60, 61]. While this older concept
has been useful for focusing attention on proinﬂammatory
and proﬁbrotic mechanisms in fatty liver disease, it does not
account for why the majority of cases of simple steatosis
d on o tp r o g r e s st oN A S Ho rc i r r h o s i sa n di tf a i l st ot a k e
into account the cytotoxic and proinﬂammatory properties
of several lipid species. Thus, a more encompassing con-
cept about NASH pathogenesis considers that the proﬁle
of lipid molecules in NASH diﬀers from that of simple
steatosis, acknowledging that TG is a nontoxic safe stor-
age form of lipid in tissues such as the liver but that
other molecules (candidates include free fatty acids (FFA),
toxic sphingophospholipids-like ceramide, diacylglycerides
(DAG), free cholesterol, and oxysterol metabolites) could
mediate tissueinjurydirectly,a processtermed“lipotoxicity”
[62]. Lipotoxicity is also favoured as the major pathway for
pancreatic beta cell injury in T2D [62–66] and as part of the
process of atherogenesis and cardiac toxicity with metabolic
syndrome [62].
4.1. Mechanism of Steatosis. Accumulation of fat in the liver
represents an imbalance in hepatic lipid turnover. The liver
playsapivotalroleinlipidmetabolism.Ittakesupcirculating
free fatty acids and other lipids that arise from intestinal
uptake/dietary sources, from lipolysis of peripheral storage
sites (adipose tissue) and de novo synthesis (lipogenesis). The
liver then exports the lipid for storage in adipose stores as
triglyceride-rich very low density lipoproteins (VLDL). The
mechanisms potentially contributing to hepatic steatosis are
summarised in Figure 1.
Steatosis occurs when FFA supply to the liver (from die-
tary intake, peripheral lipolysis, and de novo lipogenesis)
exceeds hepatic FFA elimination (via oxidation, re-ester-
iﬁcation, and excretion as very low density lipoproteins
(VLDL)). These pathways have recently been reviewed and
will only be discussed brieﬂy here [11, 12, 26, 67]. Kinetic
studies indicate that approximately 75% of hepatic lipids
(TAG/TG) in obese patients with NAFLD comes from pe-
ripheral sites (60% from nonesteriﬁed free fatty acids from
lipolysis and 15% from diet), with approximately 25%
arising from de novo lipogenesis [68]. The latter process is
governed by several nuclear transcription factors that are
activated by insulin (in the case of sterol regulatory element
binding proteins (SREBP)1and2)andglucose(inthecaseof
carbohydrate-responsive sterol regulatory element binding
protein(ChREBP)1)[11,12,69].BothSREBP1andChREBP
activate fatty acid synthase (FAS), the rate limiting step in
biosynthesisoflongchainfattyacids,whileSREBP2regulatesCurrent Gerontology and Geriatrics Research 5
cholesterol biosynthesis. These pathways provide a partial
explanation why insulin resistance and premetabolic syn-
drome (which is hyperinsulinemia and glucose intolerance)
arestronglyassociatedwithsteatosis.Amoreimportantcon-
tribution may come from dysregulation or “failure” of pe-
ripheral adipose tissue storage sites leading to store excess
energy as TG, to abnormal lipid partitioning to the liver and
other nonphysiological storage sites like muscles [12].
Severalstudieshaveclearlyindicatethatthedevelopment
of NAFLD and of metabolic syndrome is more closely linked
tothepatternoffatdistributionthantototalbodyfat.Inpar-
ticular, central (or visceral) adiposity is strongly implicated
in the development of both hepatic steatosis and metabolic
syndrome [17, 60, 70]. Clinical studies have also highlighted
the adverse contribution of visceral adipose tissue (VAT) to
the metabolic and liver complications of overweight/obesity
[48, 71]. Similarly, in ob/ob (leptin deﬁcient) mice, which
are hyperphagic, develop insulin resistance and have severe
steatosis [48], an adiponectin transgene (which restored
normal serum adiponectin levels) expanded subcutaneous
adipose and worsened obesity, but improved metabolic
indices, such as glycemic control, in association with amelio-
ration of NAFLD [72]. In other murine experiments, using
C57B/6 mice, Tran et al. found transplanting subcutaneous
adipose tissue (SAT) to a VAT location, or to a lesser extent
to another SAT location, improved insulin sensitivity and
reduced body weight of recipient animals. This indicates
possible intrinsic physiological diﬀerence in the adipocytes
between the two sites [47].
The deleterious metabolic eﬀect of increased VAT
canbepartiallyexplainedbydysregulationofadipocytokines
(TNF-α,leptin,resistin,andmostnotablyadiponectin).This
results from increased recruitment of inﬂammatory cells,
particularly macrophages [73] in the setting of stressed and
hypertrophic adipocytes caused by overnutrition and obesity
[74]. VAT secretes more proinﬂammatory cytokines (TNF-
α, IL-6, and monocyte chemoattractant protein-1 (MCP1)),
and this, coupled with direct drainage to the liver via the
portal circulation, emphasizes the ability of VAT to directly
impair hepatic insulin signaling and promote inﬂamma-
tion.TNF-αcanactivatebothnuclearfactor-kappaB(NFκB)
and c-jun N-terminal kinase (JNK), promoting serine phos-
phorylation of the insulin receptor substrate which directly
impairs insulin signalling. Additionally, MCP-1 can activate
inﬂammatory pathways and promote hepatocyte TG accu-
mulation directly.
Insulinresistanceinadiposetissueallowsinappropriately
sustained lipolysis with release of FFA, which are shunted to
the liver at times when the liver is programmed for lipogene-
sis rather than for fat disposal [66]. Adipose inﬂammation,
coupled with hepatic insulin resistance, is one of many
possible connections linking adipocytes and liver in NASH,
as addressed next [12].
Theageingprocessresultsinincreasedprevalenceofmet-
abolic syndrome and T2D, possibly via preferential fat dis-
tribution to VAT sites. These factors all culminate in dys-
regulated lipid handling by the liver, causing steatosis and
partially explaining the resultant progression of NAFLD to
NASH.
4.2. NAFLD and Insulin Resistance. Insulin resistance is
found in virtually every patient with NASH and in approxi-
mately 60% of all patients with NAFLD. The pathogenesis of
insulinresistanceinvolvesacombinationofgeneticpolymor-
phisms that inﬂuence insulin secretion and many acquired
factors, such as sedentary lifestyle, medications, chronic
illnesses, ageing, and other environmental factors which pro-
mote obesity and immobility [26, 78]. Insulin resistance,
whether acquired or genetically determined, raises serum
insulinandincreasesserumfreefattyacid(FFA)levels.Inthe
presence of a steatotic liver, the hyperinsulinemic state fails
to suppress adipose FFA ﬂux, resulting in these FFA being
taken up by the liver, driving TG production and ultimately
perpetuating more hepatic steatosis and inﬂammation when
the mechanisms for lipid storage in adipocytes become over-
whelmed[10].Asdiscussedearlier,theaccompanyinghyper-
insulinemia promotes de novo hepatic lipogenesis [79], fur-
ther promoting lipid overload in hepatocytes.
4.3. What Drives Progression to Steatohepatitis (NASH) Once
SteatosisOccurs? Signiﬁcanthepatocyteapoptosisisafeature
of NASH and forms the basis of a serum test for caspase3-
generated cytokeratin-18 fragments (a biomarker of apopto-
sis), which is being increasingly used to diﬀerentiate between
patients with NASH and those with simple steatosis [26, 62,
80]. Hepatocyte apoptosis itself triggers regenerative mecha-
nisms to replace dead hepatocytes. However, aberrant repair
in some individuals eventually leads to activation of hepatic
stellate cells (HSC) to myoﬁbroblasts and hepatic recruit-
ment of proinﬂammatory and proﬁbrogenic immune cells to
the liver [61].
As liver injury and cell death progresses, fat laden hepa-
tocytes and perisinusoidal ﬁbrosis may impair microvascular
hepatic blood ﬂow, causing decreased oxygen and nutrient
exchange, and thereby stimulating microvascular inﬂamma-
tory response and a self-perpetuating cycle of liver damage
and vascular insuﬃciency [26, 81].
These self-perpetuating cycles of inﬂammation and
apoptosis are eﬀected in some ways by adipokines, toxic lipid
species, mitochondrial dysfunction, vascular disturbance,
and possibly gut bacterial endotoxins [26]. Ageing can alter
some of these modulators, such as by changes in SAT/VAT
distribution with its eﬀect on adiponectin levels [82], re-
duced liver blood ﬂow, and reduced ability of ageing liver to
adapt to injury. Such changes could contribute to worsened
liver histology of NAFLD in older people.
5. Progressionof NAFLD: Lessons from
NaturalHistoryStudies
Although simple steatosis is generally nonprogressive [83],
the initial assessment of SS as always being benign is not
fullysupportedbycurrentevidence[53–56].Documentation
of progressive ﬁbrosis is problematic because serial liver
biopsies are necessary and there remains the possibility of
sampling error. Table 1 summarizes 4 early studies using
serial liver biopsies to assess disease activity and progression
in NAFLD/NASH. In essence, the studies have shown pro-
gression in disease activity (SS to NASH, NASH to ﬁbrosis,6 Current Gerontology and Geriatrics Research
Table 1: Disease progression in NAFLD/NASH and risk factors predicting disease progression [53–56].
Powell et al. 1990
[53]
Harrison et al. 2003
[54]
Fassio et al. 2004
[55]
Adams et al. 2005
[56]
Number of patients with serial liver biopsy 13 22 22 103
Age (years) 49 (16–70) 50.6 (33–64) 45 (20–69) 45 (19–65)
Biopsy interval (years) 1–9 N/A 1–3 0.7–21
Follow-up period (years) 1.5–21.5 1.4–15.7 3–14.3 N/A
Disease activity (%)
Unchanged 46% 50% 68% 34%
Progress 30% 32% 31.8% 37%
Regress 23% 18% 0% 29%
Risk factors associated with
NASH progression
None identiﬁed AST Obesity Obesity
BMI BMI
Low initial ﬁbrosis score
N/A: not available; AST: aspartate transaminase.
and ﬁbrosis to cirrhosis) in up to a third (30–37%) of
patients, while a quarter (23–29%) shows the reverse, that
is, histological improvement. Both obesity and BMI were
predictive of disease progression [55, 56]. Additionally, more
severe grades of baseline steatosis, elevated serum alanine
aminotransferase (ALT), platelet count, and weight gain
greater than 5kg were other predictors of disease progression
[53, 54]. However, none of these studies looked at patients
greater than 70 years old.
What is clear in NAFLD is that once advanced ﬁbrosis
has developed, the risk for hepatocellular carcinoma (HCC)
is about 5–7%. If the person is cirrhotic at time of diagnosis,
the risk of developing portal hypertension as a major com-
plication is also high; 17%, 23%, and 52% at 1, 3, and 10
years, respectively [84].
Many cross-sectional studies have sought predictors of
hepatic ﬁbrosis in NAFLD. Relevant factors include age (es-
pecially over age 50 years), BMI > 28–32kg/m2, insulin resis-
tance or T2D, and raised serum ALT [13, 14, 27, 57, 85–91].
Inmultivariateanalysis,age,BMI,arterialhypertension,ALT,
insulin resistance, and hepatic necroinﬂammatory grade
were shown to independently predict presence of ﬁbrosis
[27, 36, 57, 86, 87, 89, 91].
The other key aspect of clinical outcome studies in
NAFLD is the increased likelihood of death from cardi-
ovascular diseases (coronary heart disease, stroke) and non-
hepatic malignancy. However, liver-related mortality ranks
third in the causes of death. The risk of liver-related death
is even higher in the subgroup of patients with NASH com-
pared to those with SS (2–10% for NASH versus 0–2% for
SS) (Table 2)[ 57, 75–77].
6. Management of NAFLD in the Elderly
The cornerstone of the management of NAFLD is to correct
the disturbed metabolic milieu by encouraging an active life-
style so as to counteract increases in body weight and im-
prove insulin sensitivity. Further, treatment of coexisting
metabolic disorders like hypertension, dyslipidaemia, and
glucose intolerance/diabetes is important in the overall man-
agement plan.
6.1. Lifestyle Changes. While lifestyle changes are widely pro-
moted, adherence remains a major issue. A program of cog-
nitive behavioural therapy remains the most eﬀective tool to
obtain long-term adherence. In these programs, individuals
areeducatedtoself-managetheirdietandtoundertakemod-
erate daily physical activity [92, 93]. Compliance to modest
caloric restriction and increased physical activity result in
both sustained weight loss and improved cardiorespiratory
ﬁtness, the latter assessed by the peak oxygen consumption
(VO2 max). In one study, a 21% improvement in physical
performance measures was observed in the diet-exercise
group as compared to 12% and 15% in the diet alone and
exercise alone groups, respectively [94].
Weight loss of only 5–10% (e.g., 3.7kg in a 75kg man)
decreases liver fat by 40% in both nondiabetic and diabetic
subjects [60, 95]. Moreover, aerobic exercise reduces hepatic
fat content independent of weight loss [96]. The beneﬁcial
eﬀects on hepatic steatosis are likely a consequence of in-
creased insulin sensitivity through reduced peripheral lipol-
ysis, inhibition of lipid synthesis, and stimulation of FA oxi-
dation [97]. On the other hand, any eﬀects on hepatic in-
ﬂammation and ﬁbrosis have been inconclusive [98]. In
individuals aged over 65 years, the beneﬁcial eﬀect of diet
and exercise on physical ﬁtness, muscle strength [99], and
metabolic ﬁtness as shown by reduction in hepatic steato-
sis, serum cholesterol, high blood pressure, and improved
insulin sensitivity Shah et al. [99]h a v ea l lb e e nc o n ﬁ r m e d .
Further studies on the eﬃcacy of such interventions in clin-
ical and histological outcomes in NAFLD/NASH will be of
interest.
6.2. Pharmacotherapy—The Insulin Sensitisers. Currently,
there are no approved drugs for use in the treatment of fatty
liver or NASH. As insulin resistance is central to NAFLD,
agents that improve insulin sensitivity appear promising. To
date,twoclassesofinsulinsensitisingagents,metformin,and
thiazolidinediones (TZDs) have been evaluated.Current Gerontology and Geriatrics Research 7
Table 2: Natural history data on NAFLD.
Adams et al. 2005 [57] Ekstedt et al. 2006 [75] Ong et al. 2008 [76] Raﬁq et al. 2009 [77]
NAFLD NASH NNFL NAFLD NASH NNFL
N 435 71 58 817 72 101
Age at diagnosis (in years) 49 ±15 55 ±12 47 ±12 17+ 51 ±13 49 ±15
Males/females 213/222 30/70 47/53
Study period 1980–2000 1988–1993 1988–1994 1979–1987
Followup (in years) 7.6 ±41 3 .7 ±1.3 8.4 (median) 10.5 (median) 13.0 (median)
Advanced cirrhosis 13 (3.1%) 7 (9.8%) 0
HCC 2 (0.5%) 2 (2.8%) 0
Deaths (total) 53 (12.1%) 26 (20.3%) 80 (9.7%)
IHD 13 (2.9%) 11 (15.5%) 5 (8.6%) 20 (2.4%) 7 (12.3%) 15 (20.3%)
Non-HCC cancer 15 (3.4%) 4 (5.6%) 1 (1.7%) 19 (2.3%) 5 (8.8%) 9 (12.2%)
Liver∗ 7 (1.6%) 2 (2.8%) 0 5 (0.6%) 10 (17.5%) 2 (2.7%)
NNLF: non-NASH fatty liver (which equates with simple steatosis referred to in the text); ∗liver related mortality.
Metformincausesweightreductionandimprovesinsulin
sensitivity by decreasing hepatic glucose output and increas-
ing peripheral glucose uptake, reducing hepatic lipogenesis
and increasing hepatic fatty acid β-oxidation (by activa-
tion of AMP-activated protein kinase), and suppression of
lipogenic transcription factor, SREBP-1 [100]. Early studies
of metformin in NASH showed signiﬁcant reduction in
hepatic steatosis and ALT, but histologic follow-up data are
scarce and have not shown improvement in hepatic necroin-
ﬂammatory grades [101–103], except in one study where it
correlated with the degree of weight loss [101]. The use of
metformin in the elderly could be also problematic because
of the additional risk of severe life-threatening lactic acidosis
(5 per 100,000 prescriptions) [104]. Currently, metformin
use for NASH is not recommended [100, 105].
Thiazolidinediones are PPAR-γ agonists that exert in-
sulin-sensitizing actions on adipocytes and in the liver.
PPAR-γ agonists increase adipocyte numbers, promote their
diﬀerentiation, and facilitate uptake and storage of FFA,
thereby reducing ectopic fat deposition in liver and mus-
cles and restoring insulin sensitivity. TZDs also increase
serum adiponectin levels, with improved insulin sensitivity.
In NAFLD, the TZDs have been shown to reduce serum ALT
levels and hepatic steatosis, with some eﬀects on necroin-
ﬂammation activity, but eﬀects on hepatic ﬁbrosis have not
usually been observed; this could relate to short duration of
use, typically 6–12 months [106–109]. More recently, Ratziu
et al. extended duration of rosiglitazone for an additional
2 years in 53 patients with liver biopsy-proven NASH.
Disappointingly, even though rosiglitazone substantially
improved steatosis in the ﬁrst year, longer treatment did
not improve NASH histology despite maintained eﬀects on
insulin sensitivity and ALT levels [110]. In general, TZDs
used to treat NASH have been well tolerated, but signiﬁcant
weightgain(2–6kg)predominantlyintheSATareaoccursin
upto72%ofpatientsandthisisaconcern.Also,withregards
to the older patient with NAFLD, TZDs can precipitate
heart failure and their use is not recommended for patients
with New York Heart Association Class III and IV heart
failure [67, 111]. Rosiglitazone has been withdrawn from
the European market due to increased rates of myocardial
infarction, but not overall cardiovascular mortality in a
meta-analysis of approximately 35,000 patients from 56 ran-
domisedcontrolledtrials[112].ItsaccessisrestrictedinAus-
tralia and America [113]. Pioglitazone appears to be the safer
alternative. Troglitazone has been withdrawn worldwide due
to signiﬁcant fatal hepatotoxicity.
6.3. Bariatric Surgery. Bariatric surgery is currently recom-
mended for morbidly obese patients (BMI > 40kg/m2)a n d
for metabolic syndrome or T2D when BMI exceeds 35kg/m2
[114]. Earlier approaches to obesity included jejunoileal
bypass surgery, which was abandoned owing to unacceptable
risks of liver failure. All other types of bariatric surgical
techniques can decrease excess body weight by up to 50%,
with generally less weight loss in laparoscopic procedures
versus more invasive approaches [115–118]. This weight loss
improves insulin sensitivity and reduces the frequency and
severity of metabolic syndrome, diabetes and its complica-
tions [97]. With respect to NAFLD/NASH, follow-up liver
biopsies have shown a reduction in hepatic necroinﬂamma-
tory activity including resolution of NASH in the majority
o fc a s e sa n dr e d u c e dh e p a t i cﬁ b r o s i si ns o m e[ 119, 120].
Bariatric surgery in patients aged greater than 60 years old
is associated with signiﬁcantly increased overall morbidity
(19%) compared with those less than 60 years (11%). How-
ever, with the exception of a small subset of patients with
signiﬁcant heart disease, there is no signiﬁcant diﬀerence in
the observed-to-expected mortality ratio [121]. Therefore,
bariatric surgery can still be considered reasonable in care-
fully selected older patients, given its signiﬁcant metabolic
beneﬁts.
6.4. Is There a Role for Liver Transplantation for NASH Cir-
rhosis in the Elderly? Currently, 5–10% of liver transplants
in the USA are for patients with NASH-related cirrhosis,
while NASH is becoming an important predisposing factor
forHCC.BecauselivertransplantationforhepatitisCpeaked
at 28% in 2002 and has remained stable since [31], it has
been projected that NAFLD will become the most common8 Current Gerontology and Geriatrics Research
indication for liver transplantation in the next 20–30 years
[122]. The obesity epidemic aﬀects not only recipients, but
also potential organ donors, up to a quarter of whom have
hepatic steatosis. The prevalence of steatosis in donor livers
increases with BMI and age. Fatty change in the donor liver
is associated with higher rates of primary graft nonfunction,
likely due to the increased severity of hepatic ischemia-
reperfusion injury [81].
Optimizing body weight before transplantation is rarely
achieved and may be hazardous in patients with decompen-
sated cirrhosis. Additionally, morbidly obese patients carry
a high perioperative risk and are at increased risk for recur-
rence of progressive fatty liver disease after transplantation,
especially in the setting of immunosuppressive therapy;
hepaticsteatosisoccursinupto60%oftransplantrecipients,
with 5–10% progressing to cirrhosis and graft loss [122].
Finally, metabolic syndrome is among the most common
causes of death after all liver transplants and is likely to be
accelerated among patients with NASH as the original cause
of endstage liver disease.
The mean age for liver transplantation increased from
29 in 1985, to 41 in 1995. By 1999, 21% of liver transplant
recipients were in people aged 60 years or older [123, 124].
Studies have also shown that, with careful selection, there
are no diﬀerences in survival or length of hospital stay for
individuals over 60 years old compared to their younger
counterparts [124]. Therefore, liver transplantation may be
a possible option in carefully selected patients with NASH
cirrhosis.
7. Conclusions
Disease incidence, severity, and progression in NAFLD/
NASH are strongly associated with presence of components
of metabolic syndrome, in particular diabetes and obesity,
and are also governed by the interactive eﬀects of both
genetic background, sex, age, and environmental factors
(food intake, level of physical activity). Advanced age is
associated with disease severity and ﬁbrosis progression; a
relatively high proportion of individuals with progressive
forms of NAFLD develop cirrhosis by the time there are in
their 70s or beyond, although more data are required on the
exactrisks.AdvancedformsofNAFLD(NASHandcirrhosis)
are associated with increased standardised mortality and
a relatively high risk of liver-related deaths.
NASHisassociatedwithincreasedriskofdeathfromcar-
diovascular disease and nonliver malignancies, as well as
from liver complications. The practical implication is that
clinicians need to consider early interventions to optimise
the management of modiﬁable metabolic risk factors, like
glycemic control in T2D, hypertension, and dyslipidemia,
each of which could also contribute to disease progression
in NAFLD. For all patients with NAFLD, the cornerstone to
management remains correction of modiﬁable risk factors.
Exercise and dietary restriction can be very eﬀective in care-
fully selected patients and should be used in a multidisci-
plinary approach, involving physiotherapists, dieticians, and
occupational therapists to overcome potential physical limi-
tations in older patients, such as osteoarthritis or decreasing
mobility from other causes. The insulin sensitisers are not
approved for use in this country for treatment of NASH, and
they should be used with caution in elderly people given the
increased likelihood of coexisting medical conditions like
congestive heart failure.
Decompensated NASH cirrhosis may become the num-
ber one indication for liver transplantation in the next two
decades.Thismeansthatpatientsbeingconsideredfortrans-
plantation are likely to be much older and have longstanding
medical comorbidities related to metabolic syndrome. These
need to be assessed and managed prior to acceptance onto
a transplantation list. Transplant physicians may need to
manage weight loss prior to transplantation of the obese and
morbidlyobese,butalsowillberequiredtomanagediabetes,
osteoporosis, hypertension, dyslipidemia, immunosuppres-
sion, and the challenge of polypharmacy from prescriptions
these elderly population will inevitably require.
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